Compare Salesforce Inc (CRM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs 10X Genomics Inc — how do they compare? Salesforce Inc trades at $192.41 (market cap $161.73B), while 10X Genomics Inc trades at $58.8 (market cap $7.61B). The key difference: Salesforce Inc is far larger — about 21.3× 10X Genomics Inc's market cap, and Salesforce Inc pays a 0.89% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| CRM | TXG | |
|---|---|---|
Market Cap | $161.73B | $7.61B |
Sector | Technology | Health |
52-Week High | $266.23 | $58.57 |
52-Week Low | $150.12 | $11.34 |
Enterprise Value | $191.77B | $7.14B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.51, up 2.47% with strong technical momentum as the stock approaches resistance at $200. The company demonstrates robust fundamentals with consistent earnings beats, posting Q1 2026 EPS of $3.88 versus $3.13 expected, and maintains impressive profitability with 77.64% gross margins. Revenue growth accelerated to $37.9B in 2025 with net income reaching $6.2B, while analyst sentiment remains overwhelmingly positive with 76% buy ratings.
Outlook remains favorable with AI-driven growth catalysts and a $230.61 consensus price target offering 17% upside potential. Key risks include competitive pressures in the SaaS sector and market volatility from AI disruption concerns. The stock presents a compelling opportunity given its Rule of 44 performance metrics and strong cash flow generation of $13.1B from operations.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
